The present study demonstrated that the group using sDMARD plus steroid therapy had significantly higher all mood disorder scale scores such as HADS-D, HADS-A, mHCL, MDQ, and disease activity and functional status scale scores such as DAS28-CRP and HAQ compared to the group receiving sDMARD monotherapy. The gene discussed is CRP; the disease is mood disorder.